These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy]. Fardet L Rev Med Interne; 2013 May; 34(5):303-9. PubMed ID: 23313327 [TBL] [Abstract][Full Text] [Related]
3. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients. Morin C; Fardet L Clin Rheumatol; 2015 Dec; 34(12):2119-26. PubMed ID: 25956956 [TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. De Nijs RN Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694 [TBL] [Abstract][Full Text] [Related]
5. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Fardet L; Fève B Drugs; 2014 Oct; 74(15):1731-45. PubMed ID: 25204470 [TBL] [Abstract][Full Text] [Related]
6. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699 [TBL] [Abstract][Full Text] [Related]
7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
8. A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index. Zhang YP; Gong Y; Zeng QY; Hou ZD; Xiao ZY BMJ Open; 2015 Jun; 5(6):e006957. PubMed ID: 26041488 [TBL] [Abstract][Full Text] [Related]
9. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan. Chitre MM; Hayes W J Manag Care Pharm; 2008 Apr; 14(3):281-90. PubMed ID: 18439050 [TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-induced osteoporosis and its treatment. Pennisi P; Trombetti A; Rizzoli R Clin Orthop Relat Res; 2006 Feb; 443():39-47. PubMed ID: 16462424 [TBL] [Abstract][Full Text] [Related]
12. [Glucocorticoid-induced cutaneous adverse events]. Guillot B Rev Med Interne; 2013 May; 34(5):310-4. PubMed ID: 23312116 [TBL] [Abstract][Full Text] [Related]
13. The epidemiology of glucocorticoid-associated adverse events. McDonough AK; Curtis JR; Saag KG Curr Opin Rheumatol; 2008 Mar; 20(2):131-7. PubMed ID: 18349741 [TBL] [Abstract][Full Text] [Related]
14. Main neuroendocrine features and therapy in primary sleep troubles. Amihăesei IC; Mungiu OC Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):862-6. PubMed ID: 23272543 [TBL] [Abstract][Full Text] [Related]
15. [Prolonged corticosteroid therapy and diet]. Le Jeunne C; Aslangul E Rev Med Interne; 2013 May; 34(5):284-6. PubMed ID: 23287277 [TBL] [Abstract][Full Text] [Related]
16. Current smoking is an independent risk factor for new-onset diabetes mellitus during highdose glucocorticoid treatment. Sugiyama T; Sugimoto T; Suzuki S; Sato Y; Tanaka T; Tatsuno I Int J Clin Pharmacol Ther; 2015 Aug; 53(8):616-20. PubMed ID: 25997545 [TBL] [Abstract][Full Text] [Related]
17. Long-term systemic glucocorticoid therapy and weight gain: a population-based cohort study. Fardet L; Nazareth I; Petersen I Rheumatology (Oxford); 2021 Mar; 60(3):1502-1511. PubMed ID: 32864693 [TBL] [Abstract][Full Text] [Related]